N-(4-(2-oxo-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-1(2H)-yl)phenyl)pivalamide | 1104452-34-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-(2-oxo-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-1(2H)-yl)phenyl)pivalamide
• 英文别名: 2,2-dimethyl-N-[4-[2-oxo-4-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]oxypyridin-1-yl]phenyl]propanamide
• CAS: 1104452-34-7
• 化学式: C₂₈H₃₅N₅O₃
• 分子量: 489.618
• InChiKey: NTRORZYBWAWXLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  sodium;hydride 、 N-(4-(2-oxo-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-1(2H)-yl)phenyl)pivalamide 、 碘甲烷 在 水 、 乙酸乙酯 、 SiO2 、 二氯甲烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以to yield 10 mg of the desired product as a white solid的产率得到N-methyl-N-(4-(2-oxo-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-1(2H)-yl)phenyl)pivalamide
  参考文献：
  名称：

  PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS

  摘要：

  提供了新的化合物，它们是GPR119 G蛋白偶联受体调节剂。GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂疗法的疾病方面非常有用。这些新的化合物具有结构式I或结构式IA。

  公开号：

  US20120258959A1
• 作为产物：
  描述：

  1-(5-propylpyrimidin-2-yl)piperidin-4-yl methanesulfonate 在 copper(l) iodide 、 8-羟基喹啉 、 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 25.0h， 生成 N-(4-(2-oxo-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-1(2H)-yl)phenyl)pivalamide
  参考文献：
  名称：

  Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119

  摘要：

  G-protein-coupled receptor 119 (GPR119) is expressed predominantly in pancreatic beta-cells and in enteroendocrine cells in the gastrointestinal tract. GPR119 agonists have been shown to stimulate glucose-dependent insulin release by direct action in the pancreas and to promote secretion of the incretin GLP-1 by action in the gastrointestinal tract. This dual mechanism of action has generated significant interest in the discovery of small molecule GPR119 agonists as a potential new treatment for type 2 diabetes. Herein, we describe the discovery and optimization of a new class of pyridone containing GPR119 agonists. The potent and selective BMS-903452 (42) was efficacious in both acute and chronic in vivo rodent models of diabetes. Dosing of 42 in a single ascending dose study in normal healthy humans showed a dose dependent increase in exposure and a trend toward increased total GLP-1 plasma levels.

  DOI：

  10.1021/jm501175v

文献信息

• PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS
  申请人：Wacker Dean A.

  公开号：US20090023702A1

  公开（公告）日：2009-01-22

  Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR 119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.

  提供了一些新的化合物，它们是GPR119 G蛋白偶联受体调节剂。GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR 119 G蛋白偶联受体调节剂疗法的疾病方面非常有用。这些新的化合物具有结构式I或结构式IA。
• US8003796B2
  申请人：——

  公开号：US8003796B2

  公开（公告）日：2011-08-23
• US8232404B2
  申请人：——

  公开号：US8232404B2

  公开（公告）日：2012-07-31
• US8513424B2
  申请人：——

  公开号：US8513424B2

  公开（公告）日：2013-08-20
• Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1<i>H</i>)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119
  作者：Dean A. Wacker、Ying Wang、Matthias Broekema、Karen Rossi、Steven O’Connor、Zhenqiu Hong、Ginger Wu、Sarah E. Malmstrom、Chen-Pin Hung、Linda LaMarre、Anjaneya Chimalakonda、Lisa Zhang、Li Xin、Hong Cai、Cuixia Chu、Stephanie Boehm、Jacob Zalaznick、Randolph Ponticiello、Larisa Sereda、Song-Ping Han、Rachel Zebo、Bradley Zinker、Chiuwa Emily Luk、Richard Wong、Gerry Everlof、Yi-Xin Li、Chunyu K. Wu、Michelle Lee、Steven Griffen、Keith J. Miller、John Krupinski、Jeffrey A. Robl

  DOI：10.1021/jm501175v

  日期：2014.9.25

  G-protein-coupled receptor 119 (GPR119) is expressed predominantly in pancreatic beta-cells and in enteroendocrine cells in the gastrointestinal tract. GPR119 agonists have been shown to stimulate glucose-dependent insulin release by direct action in the pancreas and to promote secretion of the incretin GLP-1 by action in the gastrointestinal tract. This dual mechanism of action has generated significant interest in the discovery of small molecule GPR119 agonists as a potential new treatment for type 2 diabetes. Herein, we describe the discovery and optimization of a new class of pyridone containing GPR119 agonists. The potent and selective BMS-903452 (42) was efficacious in both acute and chronic in vivo rodent models of diabetes. Dosing of 42 in a single ascending dose study in normal healthy humans showed a dose dependent increase in exposure and a trend toward increased total GLP-1 plasma levels.